Recent Company News

• 02:37 AM ET May 02, 2025
  

  Bayer AG upgraded to buy from neutral at BofA (€23.03, 0.00)

• 04:27 PM ET May 01, 2025
  

  Cytokinetics announces new PDUFA date for Aficamten in obstructive hypertrophic cardiomyopathy ($42.92, 0.00)

• 08:07 AM ET Apr 29, 2025
  

  Bayer presents new data from post-hoc analyses on ultra-low prostate-specific antigen response in patients with metastatic hormone-sensitive prostate cancer receiving NUBEQA (darolutamide) plus androgen deprivation therapy (ADT) (€23.14, +0.16)

• 05:09 AM ET Apr 29, 2025
  

  Bayer initiates Phase I study targeting GPC3 with Ac-225 radiopharmaceutical in patients with advanced HCC (€23.10, +0.12)

• 01:04 AM ET Apr 29, 2025
  

  Bayer Crop Science Division CFO resigns (€22.98, 0.00)

• 05:03 AM ET Apr 28, 2025
  

  UK grants MA to BridgeBio Pharma for BEYONTTRA to treat ATTR-CM ($36.31, 0.00)

• 10:44 AM ET Apr 25, 2025
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Jivi (€23.09, +0.61)

• 10:29 AM ET Apr 25, 2025
  

  EMA CHMP publishes summary of opinions for April meeting

• 04:12 AM ET Apr 25, 2025
  

  Bayer expects 2025 to be the most difficult year of its turnaround, reaffirms FY sales guidance - AGM speech (€22.49, +0.01)

• 09:47 AM ET Apr 22, 2025
  

  Trump administration reportedly exploring an international reference drug pricing policy - Reuters